OrbiMed — Full Portfolio
284 tracked investments · page 1 of 2 · listed companies and verified rows first
Q32 Bio is a biotechnology company developing therapies for autoimmune and inflammatory diseases, with a scientific focus on the complement system and immune regulation in conditions such as inflammation, autoimmunity and fibrosis.
BiotechHealthtech
Shelia Violette(Founder & Chief Scientific Officer)Michael Holers(Co-founder)Jodie Morrison(Chief Executive Officer)Lee Kalowski(President & Chief Financial Officer)Maria Marzilli(Chief Business Officer)David Appugliese(Senior Vice President, Head of People)
Co-investorsAtlas VentureCU Healthcare Innovation FundOUP (Osage University Partners)Sanofi VenturesAgent Capital
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)in
Co-investorsAndreessen HorowitzAvoro Capital AdvisorsMenlo VenturesRA CapitalAvoro Ventures
Aadi Bioscience develops therapies targeting mTOR-driven diseases using precision medicine and albumin-bound nanoparticle technology, applying genomic profiling to identify patients most likely to benefit from mTOR inhibition.
BiotechHealthtechMorristown, US
Scott Giacobello(Executive Officer)Bryan Ball(Executive Officer)Dave Lennon(Executive Officer, Director)David Dornan(Executive Officer)James Murphy(Executive Officer)Stephen Pakola(Executive Officer)
Board seatChau Khuong· per SEC Form D · $41.8M raise · filed Mar 2017
Co-investors3B Future Health FundAlly Bridge GroupDecheng CapitalVivo CapitalAvoro Ventures
Adicet Bio develops allogeneic gamma delta CAR T cell therapies for patients with autoimmune diseases and cancer.
BiotechHealthtechMenlo Park, US
Aya Jakobovits(Executive Officer, Director)Nathan Hubbard(Executive Officer)
BoardFlorent Gros(Director)Erez Chimovits(Director)in
Board seatJonathan SilversteinCarl Gordon· per SEC Form D
Co-investorsForesite CapitalPontifax Venture CapitalQuan CapitalaMoonNovartis Venture Fund
Arvinas is a biopharmaceutical company developing PROTAC protein degrader therapies, with a pipeline focused on oncology and neurology.
BiotechHealthtechNew Haven, US
Sean Cassidy(Executive Officer)Manuel Litchman(Executive Officer, Director)
BoardLiam Ratcliffe(Director)Tim Shannon(Director)inKush Parmar(Director)
Board seatStephen Squinto· per SEC Form D · $55M raise · filed Apr 2018
Co-investors5AM VenturesAccess BiotechnologyCanaan PartnersConnecticut InnovationsNextech InvestRA Capital+1 more
BiotechLa Jolla, US
Eric W. Roberts(Executive Officer, Director)Kenneth A. Stauderman(Executive Officer)Daniel Geffken(Executive Officer)A. Rachel Leheny(Executive Officer, Director)Sudarshan Hebbar(Executive Officer)Michael J. Dunn(Executive Officer)
Board seatChau Khuong· per SEC Form D · $80M raise · filed Aug 2019
Co-investorsSanderling VenturesClarus
Compass Therapeutics develops antibody-based therapies targeting the tumor microenvironment to treat cancer.
BiotechHealthtechCambridge, US
Schuetz Thomas(Executive Officer, Director)Errik Anderson(Executive Officer, Director)Steve Tregay(Director)
Board seatStephen SquintoCarl Gordon· per SEC Form D
Co-investorsBioBritF-Prime CapitalForesite CapitalvenBio PartnersVivo Capital
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsBay City CapitalNew Enterprise Associates (NEA)RA CapitalArix Bioscience
BiotechLexington, US
Jasbir S. Seehra(Executive Officer, Director)
BoardJulius Knowles(Director)Alon Lazarus(Director)inOhad Hammer(Director)Ran Nussbaum(Director)
Board seatCarl Gordon· per SEC Form D · $56M raise · filed Mar 2020
Co-investorsArkin CapitalForesite Capital
BiotechAustin, US
Matthew Winkler(Director)Sinil Kim(Executive Officer)Paul Lammers(Executive Officer, Director)Jon Irvin(Executive Officer)Casi DeYoung(Executive Officer)
BoardMichael Powell(Director)
Board seatChau Khuong· per SEC Form D · $80M raise · filed Jun 2019
Co-investorsPfizer Venture Investments
Nextcure is a clinical-stage biopharmaceutical company developing immunotherapies targeting IO pathways, with a focus on oncology applications.
BiotechBeltsville, US
Michael Richman(Executive Officer, Director)Timothy Mayer(Executive Officer)Udayan Guha(Executive Officer)Steven P. Cobourn(Executive Officer)Sourav Kundu(Executive Officer)Kevin Shaw(Executive Officer)
Board seatChau Khuong· per SEC Form D · $93.4M raise · filed Nov 2018
Co-investorsBay City CapitalCanaan PartnersLAVLilly Asia VenturesPfizer Venture InvestmentsQuan Capital+2 more
Prelude Therapeutics is a precision oncology company developing cancer treatments for areas of high unmet need, with a pipeline including selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors.
BiotechHealthtechNewark, US
Krishna Vaddi(Executive Officer, Director)
BoardPaul Friedman(Director of Issuer)
Board seatDavid Bonita· per SEC Form D
Co-investorsThe Innovation Space
San Jose, US
Mark Reiley(Director)Jeffrey Dunn(Executive Officer, Director)Mark A. Reiley(Director)Jeffrey W. Dunn(Executive Officer, Director)Laura Francis(Executive Officer)Robert E. Johnson(Executive Officer)
Board seatDavid Bonita· per SEC Form D · $21M raise · filed Jun 2016
Co-investorsArboretum Ventures
Spruce Biosciences develops and commercializes therapies for serious neurological and endocrine disorders with unmet medical need, with a lead investigational enzyme replacement therapy (TA-ERT) for Mucopolysaccharidosis Type IIIB (Sanfilippo Syndrome Type B).
BiotechHealthtechSouth San Francisco, US
Javier Szwarcberg(Executive Officer, Director)Samir Gharib(Executive Officer)RICHARD KING(Executive Officer, Director)
BoardSimpson Camilla(Director)Tiba Aynechi(Director)inBali Muralidhar(Director)in
Board seatDina Chaya· per SEC Form D · $53.6M raise · filed Feb 2023
Co-investorsAisling CapitalHealthCapRiverVest Venture PartnersAbingworthNorwest Venture Partners
Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.
BiotechDeep TechMedical DevicesCambridge, US
Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)
Board seatChau Khuong· per SEC Form D · $42M raise · filed May 2017
Co-investorsAtlas VentureNew Enterprise Associates (NEA)NSG VenturesPfizer Venture InvestmentsSofinnova VenturesSolasta Ventures
Adaptive Biotechnologies applies the genetics of the adaptive immune system to diagnostics and therapeutics, translating immune-system data into clinical insights for clinicians and biopharma companies.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesSeattle, US
Chad Robins(Executive Officer, Director)Harlan Robins(Executive Officer)inKathleen Determann(Executive Officer)Dean Schorno(Executive Officer)Chris Carlson(Executive Officer)
BoardArnold Levine(Director)
Co-investorsDecheng CapitalFMG CapitalForesite CapitalKhosla Ventures
Alumis is a clinical-stage biopharmaceutical company developing a late-stage portfolio of targeted therapies for immune-mediated diseases.
AI & Machine LearningBiotechDigital HealthHealthtechLongevitySouth San Francisco, US
Martin Babler(President, Chief Executive Officer and Chairman of the Board)Mark Bradley(Chief Development Officer)Kolbot By(SVP, Head of Technical Operations)Jack Danilkowicz(Chief Commercial Officer)Jörn Drappa(Chief Medical Officer)David M Goldstein(Chief Scientific Officer)
Co-investorsForesite CapitalNextech InvestSamsara BioCapitalSR One Capital ManagementvenBio PartnersWestlake Village BioPartners+1 more
Aura Biosciences develops Virus-Like Drug Conjugates (VDCs), a platform using Virus-Like Particles conjugated with drugs or loaded with nucleic acids to target solid tumors.
BiotechHealthtechMedical DevicesCambridge, US
Elisabet de los Pinos, Ph.D.(Executive Officer, Director)Elisabet de los Pinos, Ph.d.(President and Treasurer)Elisabet de los Pinos(Founder)inMichael Wyzga(Executive Officer)Dale Pfost, Ph.D.(Director)Alan E. Walts, Ph.D.(Director)
Co-investorsAdvent Life SciencesChiesi VenturesDroia VenturesForesite CapitalJazzya InvestmentsMedicxi+4 more
AVITA Medical develops therapeutic acute wound care technologies, including the FDA-approved RECELL System that uses a patient's own skin to create a Spray-On Skin cell suspension for treating thermal burn wounds and full-thickness skin defects.
BiotechHealthtechMedical DevicesMelbourne, US
Dale A Sander(Executive Officer)
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Kristen Fortney(Executive Officer, Director)inEric Morgen(Director)Dov Goldstein(Executive Officer)
BoardPatrick Enright(Director)in
Co-investorsAndreessen HorowitzElad GilFelicis VenturesIA Seed VenturesLongitude CapitalPear VC+2 more
BiomX builds a portfolio of defense and security companies through subsidiaries, partnerships, and acquisitions, focusing on detection systems, aerial technologies, and infrastructure security.
AI & Machine LearningBiotechCybersecurityDeep TechDefense TechHardware
Jonathan Solomon(Chief Executive Officer)Merav Bassan(Chief Development Officer)Marina Wolfson(Chief Financial Officer)Jesse Goodman(Director)Alan Moses(Director)Jonathan Leff(Director)
Co-investorsAMR Action FundBaruch Future VenturesNSG Ventures8VC
Caris Lifesciences operates a precision oncology platform that analyzes DNA, RNA and proteins across tissue and blood to profile a patient's cancer and match treatments and clinical trials.
AI & Machine LearningBiotechHealthtech
David Dean Halbert(Chairman, Founder and CEO)
Co-investorsCoatue ManagementSilver Lake PartnersSixth Street
Cullinan Therapeutics is a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer, with a pipeline that includes CD19- and BCMA-targeted T cell engagers.
BiotechHealthtech
Co-investorsForesite CapitalNextech InvestBiotechnology Value Fund
Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.
BiotechHealthtech
John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)
Co-investorsAccess BiotechnologyAtlas VentureBain Capital Life SciencesForesite CapitalFrazier Life Sciences
Emergent BioSolutions is a public health company that develops, manufactures, and supplies medical countermeasures for national security and preparedness, along with commercialized products addressing threats such as the opioid epidemic.
Advanced ManufacturingBiotechHealthtechGaithersburg, US
Fuad El-Hibri(Director, Executive Officer)Robert G Kramer(Executive Officer)Katherine Strei(Executive Officer)Adam R Havey(Executive Officer)Daniel J Abdun-Nabi(Executive Officer, Director)Zsolt Harsanyi(Director)
Co-investorsAdvent Life Sciences
Enliven Therapeutics is a biopharmaceutical company developing small molecule precision therapeutics, including ELVN-001, a selective active site inhibitor of BCR::ABL1 for patients with chronic myeloid leukemia (CML).
BiotechHealthtechBoulder, US
Co-investors5AM VenturesPfizer Venture InvestmentsRoche Venture FundARCH Venture Partners
Insmed is a biopharmaceutical company that provides grants and charitable funding to support healthcare provider education and patient care initiatives focused on nontuberculous mycobacterial lung disease, non-cystic fibrosis bronchiectasis, and other serious lung diseases.
BiotechDigital HealthHealthtechMedical Devices
Co-investorsBessemer Venture PartnersF-Prime CapitalForesite CapitalProspect Venture PartnersNVIDIA
BiotechHealthtechMiami, US
Patrick Verta(Executive Officer)Pete Ligotti(Executive Officer)Mike Lawless(Chief Financial Officer)Shane Gleason(Executive Officer)Marvin Slosman(President and Chief Executive Officer)Andrea Tommasoli(Chief Operating Officer)
NeuroPace is a commercial-stage medical device company that develops the RNS System, a brain-responsive neurostimulation platform delivering real-time treatment at the seizure source for patients with drug-resistant epilepsy and other brain disorders.
Digital HealthHardwareHealthtechMedical DevicesMountain View, US
Rebecca Kuhn(Executive Officer)Frank Fischer(Executive Officer, Director)Vince Burgess(Director)Renee Ryan(Director)Ray Larkin(Director)Greg Garfield(Director)
Co-investorsAccelmed PartnersNew Enterprise Associates (NEA)
HealthtechCerritos, US
Robert Carter(Executive Officer)Jeremy Castle(Executive Officer)Daniel Virnich(Executive Officer, Director)Yale Podnos(Executive Officer)Brad Hively(Director)Mihir Shah(Executive Officer)
Shattuck Labs is a biopharmaceutical company developing a DR3 blocking antibody for the treatment of Inflammatory Bowel Disease and other inflammatory and immune-mediated diseases.
BiotechAustin, US
Josiah Hornblower(President/CEO)
BoardWalter Loewenbaum(Director)
Co-investorsEcoR1 CapitalHatteras Venture PartnersT. Rowe Price
HealthtechLaguna Hills, US
Bjarne Bergheim(Executive Officer, Director)John McGaugh(Executive Officer)John Bostjancic(Executive Officer)Hugh Neuharth(Executive Officer)
BoardOlav Bergheim(Director)Olav B. Bergheim(Director)
Co-investorsEssex Woodlands Healthcare PartnersFjord VenturesGeneral AtlanticMeritech Capital PartnersWelsh, Carson, Anderson & Stowe
BiotechMalvern, US
Antony Koblish(Executive Officer, Director)Francis Conway(Executive Officer)Maarten Persenaire(Executive Officer)Christine Arasin(Executive Officer)Vince Burgess(Director)
BoardKevin Rakin(Director)
Co-investorsCheckmate Capital Group LLCEssex Woodlands Healthcare PartnersSignet Healthcare Partners1315 Capital
Traws Pharma is a clinical-stage biopharmaceutical company developing oral small molecule antiviral therapies for respiratory viral diseases.
BiotechHealthtech
Upstream Bio is a clinical-stage biotechnology company developing verekitug, an antagonist that targets the TSLP receptor to inhibit pro-inflammatory signaling.
BiotechHealthtech
Rand Sutherlandin
Co-investorsAccess BiotechnologyBain Capital Life SciencesDecheng CapitalSamsara BioCapitalTCG CrossoverVenrock Healthcare Capital Partners
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)CATHY CAREW(Executive Officer)JONATHAN PACHTER(Executive Officer)ROB GAGNON(Executive Officer)
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLightstone VenturesLongwood FundOberland Capital
Aer Therapeutics develops a science-driven therapeutic aimed at eliminating mucus plugs in the lungs to treat muco-obstructive lung diseases such as COPD and asthma.
BiotechHealthtechMedical DevicesRaleigh, US
THOMAS MATHERS(Executive Officer, Director)James Shaffer(Executive Officer, Director)Thomas Mathers(Executive Officer, Director)John Fahy(Director)in
BoardChristy Shaffer(Director)inRishi Gupta(Director)
Co-investorsHatteras Venture PartnersCanaan PartnersPappas Capital
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical Devices
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalDomain AssociatesEDB InvestmentsSection 32Frazier Life Sciences+3 more
Brenig Therapeutics is a biotechnology company developing small-molecule therapies for Parkinson's disease and other neurodegenerative disorders, using AI-driven drug discovery.
AI & Machine LearningBiotechHealthtech
Megan McGill(Chief Executive Officer)Iain Dukes(Chief Business Officer / Chairman of the Board)Nikolay Savchuk(Chief Operating Officer)Tien Dam(Chief Medical Officer)
Co-investorsNew Enterprise Associates (NEA)BGVTorrey Pines Investment
Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.
AI & Machine LearningBiotechDeep Tech
Clarissa Desjardins(Founder)
Co-investorsAlexandriaDIMENSIONBDC Thrive Venture Fund for WomenLumira Ventures
GentiBio develops engineered regulatory T-cell (EngTreg) therapies designed to reset the immune system and treat autoimmune and acute inflammatory diseases.
BiotechHealthtechMedical Devices
Jane Buckner(Scientific Co-founder (President, Benaroya Research Institute))Chandra Patel(Co-founder & SVP, Research and Development Operations)David Rawlings(Scientific Co-founder and Senior Scientific Advisor)Andy Scharenberg(Scientific Co-founder, SAB Chair)Andy Walker(President and CEO)Tom Wickham(Chief Scientific Officer)
Co-investorsNovartis Venture FundJDRF T1D FundRA Capital
i2020 Accelerator (T123 LLC) is a drug discovery accelerator that de-risks early-stage science and advances drug discovery platforms toward lead and clinical candidate stage within roughly two years, working across therapeutic areas such as oncology, immunology, and infectious diseases.
BiotechDeep TechHealthtech
Co-investorsTorrey Pines InvestmentBioGeneration Ventures
Lattice MedTech operates a medical device distribution and manufacturing platform in India, serving global brands and Indian manufacturers across specialties such as cardiology, orthopedics, general surgery, critical care, and IVD.
HealthtechLogistics & Supply ChainMedical Devices
OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages.
BiotechMedical DevicesNew York, US
Dr. Bing Yuan(Co-Founder, Chief Executive Officer)Dr. Eric Slosberg(Co-Founder, Chief Development Officer)Dr. Andy Fu(Co-Founder, Chief Business Officer)
Co-investorsCatalio Capital Management, LPF-Prime CapitalSofinnova VenturesInsight PartnersNVIDIA
Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.
BiotechHealthtechMedical Devices
Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)
Co-investorsAtlas VentureRA Capital
Sirius is a biotech company developing RNAi-based therapies focused on cardiovascular diseases for global markets.
BiotechHealthtech
Co-investorsDelos CapitalCreacion Ventures
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investors20/20 HealthCare Partners LLCBosch VenturesNew Era Capital PartnersPeregrine VenturesPitangoQuark Venture Inc.+2 more
HealthtechCarlsbad, US
Christoph Scharf(Director)Randy Werneth(Executive Officer, Director)Graydon Beatty(Executive Officer)Vince Burgess(Director)John Dahldorf(Executive Officer)
BoardAditya Puri(Director)
Board seatDavid Bonita· per SEC Form D
Co-investorsAdvent Life SciencesDeerfield Management CompanyGE VenturesIndex Ventures
Adela develops blood-based diagnostic tests that analyze cell-free DNA using whole methylome analysis to detect and monitor cancer.
BiotechDigital HealthHealthtechFoster City, US
Daniel Diniz De Carvalho(Executive Officer, Promoter)Scott Bratman(Executive Officer, Director)Anne-Renee Hartman(Founder)Alan Williams(Executive Officer)Lisa Alderson(Executive Officer, Director)Priscilla Huang(Executive Officer)
Board seatDavid Bonita· per SEC Form D
Co-investorsDecheng CapitalF-Prime CapitalDeerfield Management CompanyMenlo Ventures
BiotechCincinnati, US
Joseph H. Gardner(Executive Officer)Robert Shalwitz(Executive Officer)Joseph Gardner(Founder)inDuane Nash(Director)Kevin Peters(Executive Officer)Steve Pakola(Executive Officer)
Board seatChau Khuong· per SEC Form D · $9.2M raise · filed Apr 2016
Co-investorsCincyTechSofinnova Ventures
Clinical-stage company developing novel treatment for recurrent high-grade gliomas
HealthtechChanhassen, US
Jeremy Ling(Executive Officer)Steve Weiner(Executive Officer)Vijay Agarwal(Executive Officer, Director)William Davis(Executive Officer, Director)
BoardImran Eba(Executive Officer)in
Board seatKlaus Veitinger· per SEC Form D
Co-investorsSV Health InvestorsAction Potential Venture Capital Ltd.
Angiex develops Nuclear-Delivered Antibody-Drug Conjugate (ND-ADC) therapies for solid cancers, using a platform that delivers chemotherapeutic payloads to the nucleus of tumor cells and tumor blood vessel endothelial cells.
BiotechHealthtechMedical DevicesCambridge, US
Paul Jaminet(Executive Officer, Director)in
BoardErrik Anderson(Director)Jason Camm(Director)inJonathan Adams(Director)inFabian Hansen(Director)in
Board seatIain Dukes· per SEC Form D · $28.4M raise · filed Sep 2025
Co-investorsGreen Meadow VenturesK5 Global
BiotechSan Francisco, US
Matthew Patterson(Executive Officer, Director)
BoardSteve Squinto(Director)inKush Parmar(Director)Jonathan Leff(Director)Thomas Woiwode(Director)
Board seatJonathan Silverstein· per SEC Form D · filed Sep 2015
Co-investorsAsset Management CompanyRA CapitalvenBio PartnersDeerfield Management CompanyVenrock
Creates gene therapies that integrate therapeutic genes into patients' genomes to treat genetic disorders.
HealthtechWatertown, US
Thomas Barnes(Chief Executive Officer/President)Richard Morris(Chief Financial Officer)
BoardRoy Amariglio(Director)Nick Olsen(Director)Michal Silverberg(Director)
Board seatStephen Squinto· per SEC Form D · $85M raise · filed Mar 2026
Co-investorsDeep InsightNovartis Venture Fund
Belenos Biosciences develops long-acting bispecific antibody therapeutics for chronic inflammatory diseases such as COPD, asthma, atopic dermatitis, CRSwNP, and CSU.
BiotechHealthtechNew York, US
Donnie McGrath(CEO & Co-Founder)Megan Dow(COO & Co-Founder)Tania Dimitrova(CFO & Co-Founder)Glenn Rosen(Chief Translational Officer & Co-Founder)StJohn Donnie McGrath(Executive Officer, Director)
BoardBo Chen(Director)
Board seatCarl Gordon· per SEC Form D
BiotechLaval
Francois Desjardins(Vice President, Finance)Denis Garceau(Senior Vice President, Drug Development)Franklin Berger(Director)Roberto Bellini(President and Chief Executive Officer)Joseph Rus(Director)Youssef L. Bennani(Director)
Board seatChau Khuong· per SEC Form D · $24M raise · filed Jan 2019
Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.
BiotechHealthtechMedical DevicesWestminster, US
Andrew J Tofe(Director)Britt Pearson(Executive Officer)Jeff Marx(Executive Officer)Glen Kashuba(Executive Officer, Director)Jerome Connor(Executive Officer)Andrew Handwerker(Executive Officer)
Board seatChau KhuongJonathan Silverstein· per SEC Form D · $4M raise · filed Feb 2015
Chemomab Therapeutics is a clinical-stage biotechnology company developing therapeutics for fibro-inflammatory diseases.
BiotechTel Aviv
Adi Mor(Executive Officer, Director)Adi Mor George(Executive Officer, Director)Jill Quigley(Director)Sigal Fattal(Executive Officer)Matthew Frankel(Executive Officer)Arnon Aharon(Executive Officer)
Board seatStephen Squinto· per SEC Form D
Co-investorsAltium Capital
BiotechDorval
Francois Nader(Director)Donna Roy Grogan(Executive Officer)Jean-Francois Pariseau(Executive Officer, Director)Michael Singer(Executive Officer)David P. Bonita(Director)inRobert Heft(Director)
Board seatDavid Bonita· per SEC Form D · $60M raise · filed Jul 2015
Bothell, US
Board seatTal Zaks· per SEC Form D · $84.8M raise · filed Mar 2025
Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets.
BiotechDeep TechSan Diego, US
Sergio Duron(Co-Founder & Chief Executive Officer)inSanford Madigan(Co-Founder, President & Chief Business Officer)inAnaleah Heidt(Chief Scientific Officer)
BoardMarcos Milla(Director)Jay Lichter(Director)Tighe Reardon(Executive Officer)
Board seatStephen Squinto· per SEC Form D · $15M raise · filed Sep 2025
Co-investorsFrazier Life SciencesLightspeed Venture PartnersSamsara BioCapitalAvalon BioVenturesPappas CapitalPfizer Venture Investments
BiotechPhiladelphia, US
William Hinshaw(Executive Officer, Director)Jeff Sacher(Chief Financial Officer)Matthew Ros(Chief Executive Officer, President and Secretary)
BoardGiovanni Mariggi(Director)inMatthew Foy(Director)
Board seatErez Chimovits· per SEC Form D · $46M raise · filed May 2025
Co-investors3B Future Health FundMedicxi
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)
BoardJean George(Director)Jason Rhodes(Director)
Board seatCarl Gordon· per SEC Form D
Co-investorsLightstone VenturesAtlas Venture
BiotechPennington, US
Chris Duke(Mr. Duke is the Chief Operating Officer of the Issuer.)Dale Ludwig(Mr. Ludwig is the Chief Scientific Officer)Anuj Goswami(Mr. Goswami is the General Counsel and Secretary)Claudine Prowse(Ms. Prowse is the Chief Financial Officer)Gary Sender(Director)Julie Hambleton(Director)
Board seatChau Khuong· per SEC Form D · $55M raise · filed Dec 2021
BiotechBurlingame, US
John Celebi(Executive Officer)Mary Haak-Frendscho(Executive Officer, Director)
BoardJohn Diekman(Director)inDavid Goeddel(Director)Robert Schreiber(Director)
Board seatCarl Gordon· per SEC Form D · $6.3M raise · filed Jan 2015
Co-investors5AM VenturesThe Column Group
BiotechBoston, US
Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)
BoardOtello Stampacchia(Director)in
Board seatIain DukesDavid Bonita· per SEC Form D · $75M raise · filed Jul 2025
Co-investorsAtlas VentureBiotechnology Value FundForesite CapitalOmega FundsRTW Investments L.P.
Inspire Medical Systems develops an FDA-approved implantable device that treats obstructive sleep apnea (OSA) by working with the patient's natural breathing, controlled via a small remote and intended for patients for whom CPAP is not effective.
Digital HealthHealthtechMedical DevicesGolden Valley, US
Timothy Herbert(Executive Officer, Director)Tim Herbert(Founder)inGlen Nelson(Director)Benjamin Pless(Director)Mark Fletcher(Director)Edward Shuck(Director)
Board seatChau Khuong· per SEC Form D · $37.5M raise · filed Nov 2016
Co-investorsAmzak HealthAPERTURE Venture PartnersUS Venture Partners
Neurogastrx is a late clinical-stage biopharmaceutical company developing therapies for patients with serious gastrointestinal (GI) disorders that have limited treatment options.
BiotechHealthtechWoburn, US
Cyril De Colle(Founder)inCYRIL DE COLLE(Executive Officer, Director)JAMES DETORE(Executive Officer)JAMES O'MARA(Executive Officer, Director)PAUL ROGERS(Executive Officer)
BoardDAVID ALLISON(Director)
Board seatKevin KochKlaus Veitinger· per SEC Form D
Co-investors5AM VenturesSamsara BioCapitalvenBio PartnersVivo CapitalvenBio Global StrategicWestlake Village BioPartners
Noctrix Health develops clinically validated wearable therapeutics for managing chronic neurological disorders, with its first product Nidra receiving FDA De Novo authorization and dedicated CMS HCPCS codes.
Digital HealthMedical DevicesWellness & FitnessPleasanton, US
Shri Raghunathan(Founder)in
Board seatChau Khuong· per SEC Form D
Co-investorsAngelini VenturesBlue Venture FundsTreo Ventures, LlcZühlke VenturesBridge BankSandbox Clinical Ventures+1 more
Perfuse Therapeutics is a biotechnology company developing a therapy to improve blood flow to the retina, targeting ocular diseases such as glaucoma and diabetic retinopathy.
BiotechMedical DevicesSan Francisco, US
BoardChristy Shaffer(Director)Sevgi Gurkan(Executive Officer, Director, Promoter)in
Board seatChau Khuong· per SEC Form D
Co-investorsAccess BiotechnologyCatalio Capital Management, LPHatteras Venture PartnersLAVLilly Asia VenturesHatteras
BiotechBoston, US
Darlene Deptula-Hicks(Executive Officer)Stephen S. Yoder(Executive Officer, Director)Darlene M. Deptula-Hicks(Acting Chief Financial Officer)Christina Takke(Director)
BoardSteven Prelack(Director)
Board seatChau Khuong· per SEC Form D · $16.5M raise · filed Jun 2016
HealthtechNew York, US
ASA ABELIOVICH(Executive Officer, Director)
Board seatCarl GordonPeter ThompsonMona Ashiya· per SEC Form D · $65M raise · filed Mar 2018
Promentis Pharmaceuticals is a privately-held biopharmaceutical company developing oral compounds targeting the System xc- glutamate pathway to treat neuropsychiatric disorders.
BiotechHealthtechMental HealthMilwaukee, US
David Baker, PhD(Director)Daniel Lawton(Executive Officer, Director)Tom Beck(Executive Officer, Director)Chad Beyer(Executive Officer)Chad E Beyer, PhD(Executive Officer, Director)
Board seatKlaus Veitinger· per SEC Form D · $6M raise · filed Dec 2019
Co-investorsAisling CapitalF-Prime Capital
Rhythm Pharmaceuticals is a biopharmaceutical company that develops precision medicines and treatment options for patients with rare neuroendocrine diseases, including hyperphagia and obesity.
BiotechHealthtechBoston, US
Keith Gottesdiener(Executive Officer, Director)Bart Henderson(Mr. Henderson is the President and Treasurer of the Issuer.)
BoardEdward T. Mathers(Director)inNeil Exter(Director)inTodd Foley(Director)
Board seatJonathan Silverstein· per SEC Form D · $40M raise · filed Dec 2015
Co-investorsForesite CapitalHEALTHCARE ROYALTY PARTNERSNew Enterprise Associates (NEA)Pfizer Venture InvestmentsThird Rock Ventures
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing targeted therapies for cardiometabolic disease.
BiotechHealthtechMedical DevicesPortland, US
Robert Jacks(Executive Officer, Director)David Aaron Katz(Executive Officer, Director)
BoardJonathan Root(Director)inNiall O'Donnell(Director)inZach Scheiner(Director)in
Board seatKlaus Veitinger· per SEC Form D
Co-investorsRA CapitalRiverVest Venture PartnersUS Venture Partners
HealthtechStamford, US
Daniel S. Lynch(Executive Officer, Director)Saqib Islam(Executive Officer, Director)Michael Greco(Executive Officer)
BoardDeval Patrick(Director)Carl L Gordon(Director)in
Board seatStephen SquintoCarl Gordon· per SEC Form D · $125M raise · filed Apr 2019
Co-investorsBain Capital Life SciencesPfizer Venture Investments
BiotechNewark, US
Robert Jacks(Executive Officer)Joseph Amprey(Executive Officer)
BoardThomas Beck(Director)Ben Auspitz(Director)
Board seatRishi GuptaKlaus Veitinger· per SEC Form D · $6M raise · filed May 2016
BiotechCambridge, US
William C. Shakespeare(Director)
BoardIain Dukes(Executive Officer, Director)inMichael Rome(Director)
Board seatCarl Gordon· per SEC Form D
Co-investorsForesite CapitalLongitude CapitalNextech Invest
Thrombolex develops endovascular catheters using pharmaco-mechanical technology to treat arterial and venous thromboembolic (A+VTE) conditions by dissolving blood clots.
BiotechHealthtechMedical DevicesKingston, US
Riyaz Bashir(Innovator / Creator of BASHIR Endovascular Catheters)John Cerminaro(Executive Officer)Michael J. Cerminaro(Executive Officer, Director)Marvin Woodall(Executive Officer, Director)Brian G. Firth(Executive Officer, Director)Todd Richmond(Director)
Board seatDavid Bonita· per SEC Form D
Treeline develops therapeutics focused on oncology, leveraging insights from clinical practice and laboratory research.
AI & Machine LearningBiotechMedical DevicesWatertown, US
Joshua H. Bilenker(Executive Officer, Director, Promoter)Jeffrey Engelman(Executive Officer, Director, Promoter)inJosh Bilenker(Founder)in
BoardKristina Burow(Director)inAli Satvat(Director)David Schenkein(Director)in
Board seatDavid Bonita· per SEC Form D
Co-investorsAisling CapitalARCH Venture PartnersCasdin CapitalFidelity InvestmentsGV (Google Ventures)Rock Springs Capital+1 more
BiotechSouth San Francisco, US
Gerrit Klaerner(Executive Officer, Director)Melissa Miksch(Executive Officer)
BoardSandra Coufal(Director)Robert Alpern(Director)
Board seatKlaus VeitingerDavid Bonita· per SEC Form D · $55.5M raise · filed Jul 2016
Co-investorsAvoro Capital AdvisorsLongitude Capital
BiotechChicago, US
Rand Sutherland(Director)James Sullivan(Executive Officer, Director)in
BoardBernard Davitian(Director)Uya Chuluunbaatar(Director)
Board seatJonathan SilversteinStephen SquintoMona Ashiya· per SEC Form D
Co-investorsPontifax Venture Capital
ViewRay develops MRIdian A3i, an MRI-guided radiation therapy system that uses diagnostic-quality MRI imaging for real-time tissue tracking and automated beam control during cancer treatment.
HardwareHealthtechMedical DevicesOakwood Village, US
James F. Dempsey(Executive Officer, Director)James Dempsey(Secretary of the Issuer.)David Chandler(Mr. Chandler is the Chief Financial Officer of the Issuer.)Chris A. Raanes(Executive Officer, Director)Michael Brandt(Executive Officer)D. David Chandler(Executive Officer)
Board seatDavid Bonita· per SEC Form D · filed Aug 2015
Co-investorsAisling CapitalF-Prime Capital
ADARx is a clinical-stage biopharmaceutical company developing RNA-based medicines using its RNA science expertise and proprietary targeted delivery platforms to silence disease-causing genes.
BiotechMedical Devices
Co-investorsTCG CrossoverVivo Capital
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesHealthCapJeito CapitalNovo HoldingsPontifax Venture CapitalRA Capital+2 more
Adimab operates a yeast-based antibody discovery and engineering platform that produces fully human antibodies, heavy-chain antibodies, and multispecifics (including T-cell engagers) for biopharma partners.
AI & Machine LearningBiotechDeep Tech
Co-investorsGrandBanks CapitalLaunchCapitalLux CapitalPremji InvestSV Health InvestorsMithril Capital Management+1 more
BiotechBerkeley, US
Thomas Dubensky(Executive Officer)Dirk G. Brockstedt(Executive Officer)Stephen Isaacs(Executive Officer, Director)Jennifer Lew(Executive Officer)Gregory W. Schafer(Executive Officer)Gregory Schafer(Executive Officer)
Co-investorsForesite CapitalFranklin Templeton
Advanced Enzymes manufactures enzymes for a range of industries including human health and nutrition, animal nutrition, baking, food and grain processing, dairy, textile, and leather processing.
BiotechFoodTechNew Materials
Aerin Medical develops non-invasive radiofrequency treatment systems for chronic nasal conditions, offering the VivAer stylus for nasal airway obstruction and RhinAer stylus for chronic rhinitis.
HealthtechMedical DevicesMountain View, US
Matt Brokaw(CEO & President)Derrick Sung(Executive Officer)Matthew Salkeld(Executive Officer)Irina Ridley(Executive Officer)Andre Cheng(Executive Officer)Fred Dinger(Executive Officer, Director)
Co-investorsLaunchCapitalQuesta CapitalTargeted Technology FundsAlly Bridge GroupHorizon
Co-investorsFrazier Life SciencesLongitude Capital
AirStrip provides mobile and web applications that consolidate clinical data from EMRs, in-room monitors, and medical devices into a single view, giving clinicians remote access to patient waveforms, ECGs, and vital signs.
Digital HealthHealthtechMedical DevicesSan Antonio, US
Alan Portela(Executive Officer, Director)David Sachs(Director)Charles Kim(Director)Robert Morse(Director)JF Lancelot(Executive Officer)
BoardPatrick Soon-Shiong(Director)
AK Medical (爱康医疗) develops orthopedic implants and technologies, including metal 3D-printed implants with trabecular bone-like structures, Supravit HA plasma vacuum spray coatings, surgical planning software and robotics, and personalized custom orthopedic solutions.
HardwareHealthtechMedical Devices
Co-investorsDecheng Capital
Alentis Therapeutics is a clinical-stage biotech company developing anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies to treat cancer and reverse organ fibrosis.
BiotechHealthtech
Co-investorsAvego BioScience CapitalBioMedPartnersCatalio Capital Management, LPFrazier Life SciencesJeito CapitalLongitude Capital+3 more
Alterome is a clinical-stage precision oncology company developing small-molecule, alteration-specific cancer therapies, with two internally discovered drug candidates in the clinic.
AI & Machine LearningBiotechDeep TechSan Diego, US
Eric A. Murphy(Executive Officer, Director, Promoter)Ryan B. Corcoran(Director, Promoter)
BoardThilo Schroeder(Director)inCarl Gordon(Director)inArjun Goyal(Director)in
Co-investorsCanaan PartnersNextech InvestVida VenturesDigitalis VenturesNVIDIA
Altis Labs provides tools for analyzing medical imaging data to help biopharma sponsors gain insight during drug development, and supports clinicians and scientists conducting medical imaging research.
AI & Machine LearningBiotechMedical Devices
Felix Baldauf-Lenschenin
Co-investorsCreative Destruction Lab (CDL)Debiopharm Innovation FundFusionBenchstrength Partners
AnchorDx (基准医疗) develops ctDNA methylation high-throughput sequencing technology for early cancer detection, using blood and urine samples to cover more than 70% of high-incidence cancers including lung, breast, digestive-system and urinary-system cancers.
BiotechDigital HealthHealthtech
Co-investorsMarathon Venture Partners
Angitia Bio is a biopharmaceutical company developing therapies for musculoskeletal and other serious diseases.
Biotech
Co-investorsFrazier Life SciencesRA CapitalFrazier
Architect Therapeutics is a drug discovery company that uses C-H bond activation chemistry to synthesize novel 3D small-molecule scaffolds and screen them against difficult-to-drug targets.
BiotechDeep Tech
Jin-Quan Yu(Founder)in
Co-investorsFrazier Life Sciences
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing medicines for difficult-to-treat diseases, starting with cancers.
BiotechHealthtechMedical DevicesNewtown Square, US
Zhengbin (Bing) Yao(Executive Officer, Director)Brent Rice(Chief Commercial Officer)
BoardJason Zhang(Director)Cong Xu(Director)Stuart Lutzker(Director)
Co-investorsCatalio Capital Management, LPForesite CapitalGeneral CatalystHongShan Capital GroupLAVLilly Asia Ventures+2 more
ARS Pharma develops needle-free epinephrine treatments, including neffy, an FDA-approved epinephrine nasal spray for patients and caregivers managing allergic reactions.
BiotechHealthtechMedical DevicesSan Diego, US
Richard Lowenthal(Executive Officer, Director)Pratik Shah(Director)
BoardJonathan Leff(Director)
Co-investorsNextech InvestRA CapitalSR One Capital Management
BiotechHealthtechMedical DevicesWaltham, US
David F. Muller(Executive Officer, Director)Brian J. Roberts(Executive Officer)Rhonda J. Bracey(Executive Officer)
BoardJason Hong(Director)Jeff Dykan(Director)inAnthony Natale(Director)in
Co-investorsAPERTURE Venture PartnersLAVLilly Asia VenturesSCP Vitalife PartnersThird Point VenturesHealthQuest Capital
Avenzo Therapeutics is a clinical-stage biopharmaceutical company developing therapeutic treatments.
Biotech
Athena Countouriotis(Co-Founder, Chief Executive Officer)
Co-investorsDelos CapitalForesite CapitalINCE CapitalLongwood FundNew Enterprise Associates (NEA)Quan Capital+3 more
Averna Therapeutics is a biotechnology company developing therapeutics.
BiotechDeep TechMedical Devices
Thomas M. Barnes(CEO & Board Member)
Co-investorsDeep InsightDelos CapitalNovartis Venture Fund
Avicedar develops glyco-immune checkpoint therapeutics to treat immune-mediated diseases, with an initial focus on Macular Degeneration.
BiotechHealthtech
Co-investorsJeito CapitalLongitude CapitalDigitalis Ventures
Advanced ManufacturingBiotechHardwareLebanon, US
Tillman Gerngross(Director)Warren Kett(Executive Officer)Jon Sheller(Executive Officer)Kevin Isett(Executive Officer, Director)Jonathan Sheller(Executive Officer)Errik Anderson(Director)
Co-investorsSV Health InvestorsMithril Capital ManagementSands Capital VenturesSV Life Sciences
Azura Ophthalmics develops first-in-class keratolytic-based therapies for lid margin and ocular surface diseases, combining ophthalmologic and dermatologic approaches to treat underserved ocular indications.
BiotechHealthtechMedical Devices
BH Therapeutics is a drug development company that uses structure-based rational drug design to identify structural limitations in existing therapies and design novel chemical scaffolds to address them.
Biotech
Co-investorsVivo Capital
Braveheart develops treatments for hypertrophic cardiomyopathy and related cardiac conditions.
BiotechDigital HealthHealthtechMedical Devices
Travis Murdoch, M.D.(Chief Executive Officer and Board Director)
Co-investorsAndreessen HorowitzFrazier Life Sciences
Biobeat offers a wearable chest-patch device paired with a mobile app for 24-hour ambulatory blood pressure monitoring to confirm or unmask hypertension.
Digital HealthHealthtechMedical Devices
Arik B.(Founder)in
Co-investorsAlly Bridge GroupRaptor Group
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalSamsara BioCapitalTCG CrossoverThird Rock VenturesvenBio PartnersVida Ventures
Carrot is a global fertility and family-building platform that provides access to fertility care, maternity support, and family-building guidance for individuals and families.
FemTechHealthtechSan Francisco, US
Asima Ahmad(Founder/CMO)inTammy Sun(Founder)in
Co-investorsAll TurtlesAurumBackstage CapitalCore Venture CapitalCRV (Charles River Ventures)Expansion Venture Capital+8 more
Cellipont Bioservices is a contract development and manufacturing organization (CDMO) that provides cGMP cell therapy process development, analytical, and commercial manufacturing services, including CAR-T, from its facility in The Woodlands, Texas.
Advanced ManufacturingBiotechHealthtechThe Woodlands, US
Avalo is a clinical-stage biotechnology company developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases.
BiotechMedical DevicesBaltimore, US
Blake M. Paterson(Executive Officer, Director)Mariam Morris(Executive Officer)Ronald Marcus(Executive Officer)Uli Hacksell(Executive Officer, Director)John Kaiser(Executive Officer)James Vornov(Executive Officer)
Co-investorsNew Enterprise Associates (NEA)PETRICHOR SCION THERAPEUTICS
Charm develops open-source tools and libraries for building glamorous command-line interfaces and terminal user experiences, including CLI frameworks, UI components, and integrations with language models.
Developer Tools
Co-investorsBetaworksCavalry VenturesGradient VenturesLOWERCARBONLowercarbon CapitalBootstrapLabs+5 more
Charm is a payments and savings app that enables users to send money across different platforms (Venmo, Cash App, Zelle) through a unified interface, with funds earning interest when held in the app.
ConsumerCrypto & Web3FintechSocialNew York City, US
Gray Newfield(Founder)inNoah Newfield(Founder)in
Co-investorsY Combinator468 CapitalBootstrapLabsCavalry VenturesFuel CapitalGradient Ventures+3 more
Charm builds open-source tools and libraries for creating user interfaces and applications in the terminal, including command-line interface frameworks, markdown readers, and components for developers.
Developer Tools
Co-investorsMotive ForceNAPCavalry VenturesFuel CapitalGradient VenturesKhosla Ventures+2 more
CHARM is a biotech company developing a next-generation menin inhibitor for acute myeloid leukemia (AML), designed to address resistance seen with first-generation approaches.
AI & Machine LearningBiotechHealthtechLondon
Lakshyaditya Singh Aithani(Executive Officer, Director)
BoardRishi Gupta(Director)Nihal Sinha(Director)inMuzammil Mansuri(Director)Gary Glick(Director)
Co-investorsF-Prime CapitalNew Enterprise Associates (NEA)SR One Capital ManagementAxial VCNVentures
BiotechChelsea, US
RICHARD BATYCKY(Executive Officer)GLENN BATCHELDER(Director)BRYAN STUART(Executive Officer)MARK IWICKI(Executive Officer, Director)MARTIN FREED(Executive Officer)
BoardROB HOPFNER(Director)
Co-investorsCanaan PartnersSofinnova VenturesBay City CapitalLongitude CapitalRA Capital
BiotechBurlingame, US
Mark Rolfe(Executive Officer)Laura Shawver(Executive Officer, Director)Timothy Smith(Executive Officer)
BoardAlfred Scheidegger(Director)inPeter Thompson(Director)Carol Gallagher(Director)
Co-investorsAstellas Venture Management LLCNew Enterprise Associates (NEA)Nextech Invest5AM VenturesClarus VenturesOsage University Partners+1 more
Convergent provides an AI simulation platform for enterprise training and skill development.
AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB
Co-investorsTechstarsAndreessen HorowitzRA Capital
BiotechCambridge, US
Philip Kantoff(Executive Officer, Director)Neil Bander(Executive Officer, Director)Eric Sullivan(Executive Officer)Alexander Brown(Executive Officer)
BoardJake Simson(Director)inTal Zaks(Director)
Co-investorsInvusRA Capital
Convergent Therapeutics develops radioantibody (targeted alpha-particle radiopharmaceutical) therapies for cancer patients, including its lead candidate CONV01-α for metastatic castration-resistant prostate cancer.
BiotechHealthtech
Corteria Pharmaceuticals develops first-in-class drugs for conditions with high unmet medical need, including worsening and acute decompensated heart failure, right heart failure, sarcopenia, and obesity with complications.
BiotechHealthtech
Co-investorsFountain Healthcare PartnersInvivo Capital PartnersJeito CapitalKurma PartnersLifeArc VenturesV-Bio Ventures
Corvus is a clinical-stage biopharmaceutical company developing therapies for immune diseases and cancer.
BiotechHealthtechBurlingame, US
Richard A. Miller(Executive Officer, Director)Leiv Lea(Executive Officer)Terry G. Gould(Director)
BoardElisha (Terry) P. Gould(Director)Peter Moldt(Director)Peter Thompson(Director)
Co-investorsAvoro Capital AdvisorsForesite Capital
Landos Technology (朗来科技) is a clinical-stage drug discovery and development company with a pipeline of novel small-molecule therapies for indications including hypertension, chronic heart failure, IgA nephropathy, FSGS, chronic cough, idiopathic pulmonary fibrosis, and autoimmune diseases such as rheumatoid arthritis and psoriasis.
BiotechHealthtechWuhan, CN
Co-investorsVivo CapitalLilly Asia Ventures
Crinetics is a pharmaceutical company focused on discovering, developing, and commercializing therapies for endocrine diseases and endocrine-related conditions.
Biotech
Co-investors5AM VenturesRA Capital
Curevo Vaccine is a clinical-stage biotech company developing non-mRNA vaccines, with a lead adjuvanted subunit vaccine candidate (amezosvatein/CRV-101) for shingles and chickenpox.
BiotechHealthtech
Co-investorsAdjuvant CapitalRA CapitalSanofi VenturesHBM Healthcare InvestmentsJanus Henderson InvestorsMedicxi
Cyrus provides a mobile app for personal cybersecurity and financial protection, offering account monitoring, dark web scanning, credit monitoring across three bureaus, VPN services, and fraud support for consumers.
ConsumerCybersecurityDigital Health
Co-investorsResolute VenturesSPRINGROCK VENTURESRainfall VenturesThe Fintech FundTrinity Ventures
Cyrus Bio is a computational drug discovery company that uses protein design, deep mutagenesis, and modeling algorithms to engineer naturally occurring proteins into therapeutics.
AI & Machine LearningBiotechDeep TechSeattle, US
Javier Castellanos(Executive Officer, Director)Yifan Song(Executive Officer, Director)
BoardLucas Nivon(Executive Officer, Director)
Co-investorsAnzu PartnersArgonautic VenturesiSelect FundSPRINGROCK VENTURESStrawberry Creek VenturesThe W Fund+2 more
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue.
BiotechHealthtech
Sean A. McCarthy(Chief Executive Officer and Chairman)Marcia P. Belvin(SVP, Chief Scientific Officer)Dawn Benson(SVP, Quality and Product Manufacturing)Wayne Chu(Chief Medical Officer)Rachael Lester(SVP, Chief Business Officer)Chris Ogden(Chief Financial Officer)
Co-investorsCanaan PartnersLongitude CapitalPfizer Venture Investments
DELFI Diagnostics develops FirstLook Lung, a blood-based laboratory test for lung cancer screening that identifies genome-wide alterations in individuals eligible for screening.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesBaltimore, US
Victor Velculescu(Executive Officer, Director, Promoter)Peter Bach(Executive Officer)Jennifer Buechel(Executive Officer)Douglas Schenkel(Executive Officer)Nicholas Dracopoli(Executive Officer)
BoardRishi Gupta(Director)in
Co-investorsAV8 VenturesForesite CapitalIllumina VenturesMenlo VenturesOpen Field CapitalOUP (Osage University Partners)+3 more
Cambridge, US
Annalisa Jenkins(Executive Officer, Director)
BoardBenjamin Auspitz(Director)Donald J. Hayden(Director)Allan Fox(Director)
Co-investorsF-Prime CapitalNew Leaf Venture Partners
大米和小米 (DMHXM) operates a network of over 80 directly-run centers across more than 30 Chinese cities providing in-person early intervention and rehabilitation therapy for children with autism and developmental disorders, staffed by BCBA/BCaBA-certified therapists and experienced supervisors.
Digital HealthHealthtechWellness & FitnessShenzhen, CN
EC Healthcare offers aesthetic and medical services, including medical aesthetic products and treatments delivered with medical technology and physician involvement.
ConsumerHealthtechWellness & Fitness
Edgewise Therapeutics develops novel therapeutics for serious cardiovascular muscle diseases, including hypertrophic cardiomyopathy (HCM) and heart failure.
BiotechDigital Health
Co-investorsUS Venture Partners
Eilean Therapeutics is a small molecule oncology drug discovery company developing pan-variant therapies for hematologic malignancies (blood cancers) that target drivers of cancer resistance and escape mutations.
BiotechHealthtech
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)Matthew Fust(Director)Nancy Stagliano, Ph.D.(Director)
Co-investorsRA CapitalWestlake Village BioPartnersNVIDIA
Entero Healthcare Solutions Limited is an Indian healthcare company that filed a Draft Red Herring Prospectus with SEBI in September 2023 for a public offering.
Healthtech
Prem Sethi(Founder)in
ENYO Pharma is a clinical-stage biopharmaceutical company developing therapeutics for patients with impaired kidney function.
BiotechMedical Devices
Co-investorsAndera PartnersSofinnova PartnersBpifrance
Epigenic Therapeutics develops epigenetic medicines using an Epigenetic Modulator platform that combines nuclease-inactivated dead Cas proteins with epi-enzymes to control gene expression without cutting or altering DNA.
BiotechDeep TechHealthtech
Chloe You(Chief Medical Officer)Kelly Shi(Chief Financial Officer)
Co-investorsQiming Venture Partners
Evox Therapeutics develops exosome-based gene editing therapies using its ExoEdit platform, which combines exosome delivery with a proprietary CRISPR-based editor to treat severe neurodegenerative and other genetically-driven diseases.
BiotechDeep Tech
Co-investorsOxford Science EnterprisesPanacea VentureCowen Healthcare InvestmentsGV (Google Ventures)REDMILE
Evozyne is an AI-native biotech that designs de novo therapeutic proteins using EvoGen, a machine learning engine, and EvoLab, a high-throughput experimental facility that synthesizes and tests candidate proteins.
AI & Machine LearningBiotechDeep TechChicago, US
Aris Theologis(Executive Officer, Director)Darien Parhad(Executive Officer)Patrick J. Morris(Executive Officer, Director)Rama Ranganathan(Executive Officer, Director)
BoardJeffrey S. Aronin(Director)Antonio Gracias(Director)in
Co-investorsParagon Biosciences LLCFidelity InvestmentsNVenturesNVIDIAValor Equity Partners
Fore Biotherapeutics is a clinical-stage oncology company developing targeted cancer therapies, including its lead plixorafenib program.
BiotechHealthtechMedical DevicesPhiladelphia, US
Co-investorsLG Technology VenturesNovartis Venture FundPontifax Venture CapitalWindham Capital PartnersMedicxiSymBiosis
Forward Therapeutics is a biotech company developing a pipeline of oral small molecule therapies targeting inflammation-driven diseases.
Biotech
Frido is a consumer brand offering ergonomic and comfort products such as insoles, footwear, cushions, pillows, mattress toppers, and maternity and baby care items, sold direct to consumers and in bulk to businesses.
ConsumerDirect to ConsumerWellness & Fitness
Ganesh Sonawane(Founder)in
Frontera Therapeutics is a clinical-stage gene therapy company developing treatments for large-market and rare diseases across ophthalmology, cardiology, and neurology.
BiotechHealthtech
FUS Mobile develops the Neurolyser XR, a non-invasive, fluoroscopy-guided ablative therapy platform for treating chronic low back pain caused by arthritis of the vertebral facet joints.
HardwareHealthtechMedical Devices
Co-investorsAtlanta Technology Angels
Damora Therapeutics is a biotechnology company developing subcutaneous biologics as targeted, disease-modifying treatments for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis.
BiotechMedical Devices
Jennifer Jarrett(Chief Executive Officer & Board Director)Sherwin Sattarzadeh(Chief Operating Officer)Becker Hewes(Chief Medical Officer)Garrett Winslow(General Counsel)Jim Baker(Chief Corporate Affairs Officer)Brian Burkavage(Senior Vice President, Finance)
Co-investorsEIR VenturesHadean VenturesM VenturesSEED Capital DenmarkSunstone CapitalYsios Capital+1 more
Co-investorsHighlight Capital
Gelesis develops an oral superabsorbent hydrogel platform (OHS) built from naturally derived materials that works locally in the GI tract to influence satiety signals and support metabolic health.
BiotechDigital HealthHealthtechWellness & FitnessBoston, US
Yishai Zohar(Director, President, and Chief Executive Officer)Elliot Maltz(Treasurer)
BoardJohn LaMattina(Director)Elon Boms(Director)inMeghan Fitzgerald(Director)Robert Forrester(Director)
Co-investorsLaunchCapitalCapstar VenturesInvescoVitruvian Partners
Gracell develops CAR-T cell therapies aimed at delivering fast, deep, and durable responses for patients with cancer and autoimmune disease.
BiotechHealthtech
Co-investorsLAVLilly Asia Ventures
Harvest Integrated Research Organization (HiRO) is a full-service global contract research organization (CRO) providing end-to-end clinical trial services, including clinical data science, biometrics, site engagement, medical oversight, safety monitoring, regulatory guidance, and medical writing.
BiotechDigital HealthHealthtech
Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.
BiotechHealthtech
Co-investorsLongitude CapitalVersant VenturesWellington Management
Iambic develops AI technologies for drug discovery, using a high-throughput experimental platform to design small-molecule medicines and advance a pipeline of clinical candidates for cancers such as HER2-driven, breast, and ovarian tumors.
AI & Machine LearningBiotechDeep TechSan Diego, US
Tom Miller(Co-Founder & CEO)inFred Manby(Co-Founder & CTO)inThomas Miller(Founder)inNeil Josephson(Chief Medical Officer)inPete Olson(Chief Scientific Officer)inMichael Secora(Chief Financial Officer and Chief Corporate Development Officer)in
Co-investorsAbingworthAscenta CapitalCatalio Capital ManagementAlumni VenturesCatalio Capital Management, LPCoatue Management+4 more
iECURE develops in vivo genetic therapies using targeted gene insertion and genome editing to treat rare neurometabolic disorders, initially focusing on liver-centered metabolic conditions.
BiotechMedical Devices
ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases.
BiotechHealthtechSan Diego, US
Co-investorsAtlas Venture
Co-investorsQiming Venture Partners
Insilico Medicine applies computational and AI-based modeling to drug design and problems such as protein folding for pharmaceutical research and development.
AI & Machine LearningBiotechHealthtechHong Kong
Alex Zavoronkov(Director)Alex Zhavoronkov(Founder & CEO)
BoardNisa Leung(Director)Lennart Lee(Director)James Mellon(Director)
Co-investorsB Capital GroupB4 CapitalBOLD LongevityF-Prime CapitalGestio CapitalLAV+5 more
InventisBio (益方生物) is a biopharmaceutical company that develops small-molecule drugs, including candidates targeting KRAS G12C for lung and pancreatic cancer and treatments for moderate-to-severe plaque psoriasis.
BiotechHealthtechShanghai, CN
Xing Dai(Founder)in
Co-investorsLAVLilly Asia VenturesQiming Venture Partners
Janux Therapeutics develops precision-engineered bispecific immunotherapies, including tumor-activated T cell engagers (TRACTr), designed to modulate T cells to treat cancer and autoimmune diseases.
BiotechMedical DevicesLa Jolla, US
David Campbell, Ph.D.(Executive Officer, Director)Tighe Reardon(Executive Officer)
BoardJay Lichter, Ph.D.(Director)Jake Simson, Ph.D.(Director)Peter Thompson, M.D.(Director)Stefan Heller(Director)
Co-investorsAvalon BioVenturesSamsara BioCapital
锦欣康养 is a subsidiary of Jinxin Medical Group that operates elderly care services combining medical treatment and senior living, including institutional care, home and community care, geriatric medicine, rehabilitation, and nursing.
HealthtechLongevityWellness & FitnessChengdu, CN
Kapiva is an Ayurveda-based wellness brand that sells health and nutrition products online, with ranges covering sugar management, fitness, energy, heart and liver health, skin and hair, and women's health.
ConsumerDirect to ConsumerWellness & Fitness
Co-investorsTrifecta Capital AdvisorsVertex Ventures Sea Management Pte. Ltd.3one4 CapitalVertex Growth
Kartos Therapeutics develops targeted oral therapeutics for cancer, including Navtemadlin, an MDM2 inhibitor aimed at the MDM2-p53 interaction to treat selected solid tumors and hematological malignancies.
BiotechHealthtech
Co-investorsSR One Capital Management
Keros Therapeutics develops therapies targeting the transforming growth factor-beta (TGF-ß) family of proteins to treat disorders linked to dysfunctional TGF-ß signaling.
Biotech
Co-investorsPontifax Venture Capital
Koya Medical develops wearable compression therapy devices, including its Dayspring system, for treating conditions such as lymphedema, chronic venous insufficiency, and deep vein thrombosis.
HardwareHealthtechMedical DevicesOakland, US
Anand Doraiswamy(Executive Officer, Director)
BoardJosh Baltzell(Director)inJan Garfinkle(Director)in
Co-investorsAphelion CapitalArboretum VenturesScientific Health DevelopmentZühlke Ventures
Kumquat Biosciences is a biotech company developing small-molecule cancer therapeutics, combining drug discovery and clinical expertise to advance new oncology treatments.
BiotechSan Diego, US
Yi Liu(Executive Officer, Director)Lynn Yang(Director)
BoardCarl Gordon(Director)in
Co-investorsEcoR1 CapitalRoche Venture Fund
Develops innovative therapies for cancer and liver diseases.
Co-investorsHB VenturesInfinity Capital
Leal 360 is a retail-focused customer platform for LATAM that combines a CDP, campaign automation, loyalty programs, and NPS with an AI decision engine, connecting to a business's POS to turn purchase data into personalized marketing and loyalty actions.
AI & Machine LearningMarketing TechRetail Tech
Co-investorsAspira CapitalAxon Partners GroupCapria VenturesFuel Venture CapitalLEAP Global PartnersSalkantay Ventures+1 more
Leal Therapeutics develops first-in-class neuro-metabolic therapeutics for central nervous system disorders, including oral small molecules and antisense oligonucleotides targeting metabolic pathways underlying neuropsychiatric and neurodegenerative diseases such as schizophrenia, ALS, and Alzheimer's.
BiotechMedical DevicesWorcester, US
Co-investorsNewpath Partners
LEXEO Therapeutics develops gene therapy candidates aimed at genetically mediated cardiovascular diseases and APOE4-associated Alzheimer's disease.
BiotechHealthtech
Co-investorsLongitude Capital
LogicBio is a biotechnology company focused on research and development of treatments for rare diseases, investigating new targets, modalities, and technologies for patients and their families worldwide.
BiotechHealthtechCambridge, US
Leszek Lisowski(Executive Officer, Director)Mark A. Kay(Director)Adi Barzel(Executive Officer, Director)
BoardErez Chimovits(Director)
Co-investorsAndera PartnersPontifax Venture CapitalArix Bioscience
Lomond Therapeutics is a small molecule oncology drug discovery company developing precision hematology medicines that target resistant escape mutations in hematological cancers.
BiotechHealthtech
Lupeng Bio is a biotechnology company focused on the design and development of new anti-tumor (oncology) drugs.
BiotechHealthtech
Co-investorsLAVLilly Asia Ventures
Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.
BiotechHealthtechSouth San Francisco, US
Aetna Wun Trombley(President and CEO)Amy Bachrodt(Chief Financial Officer)Chin Lee(Chief Medical Officer)Steve Staben(Chief Scientific Officer)Sofia Touami(Chief Business Officer)Karen Flick(General Counsel)
Co-investorsREDMILEVersant VenturesBAM ElevateFranklin TempletonHBM Healthcare InvestmentsInvus+4 more
MagentaMed develops the Elevate percutaneous Left Ventricular Assist Device (pLVAD), a low-profile, high-flow arterial pump for temporary mechanical circulatory support.
HardwareHealthtechMedical Devices
Co-investorsALIVE Israel HealthTech FundFresenius Medical Care VenturesNew Enterprise Associates (NEA)RA Capital
Marksans Pharma is an Indian pharmaceutical company that researches, manufactures, and markets finished dosage pharmaceutical formulations.
BiotechHealthtech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.